The DC District Court issued its decision this evening in the APA case, siding with Avadel Pharmaceucals (Nasdaq: AVDL) and the FDA. In essence, the Court ruled in our favor on every argument presented by Jazz Pharmaceucals (Nasdaq: Jazz). As a result, LUMRYZ retains its FDA approval and the treatment of narcolepsy. This decision remains appealable and is likely to be challenged by Jazz Pharmaceucals. However, we believe the chances of a successful appeal are slim, as the judge issued a comprehensive 58-page memorandum that thoroughly examines the case details. In it, the court highlights that LUMRYZ, as a once-nightly oxybate, offers a significant improvement in paent care compared to XYWAV or XYREM, which require a middle-of-the-night dose. We are very encouraged by the court’s decision.